Anti-ERK1 + ERK2 antibody [EPR17526] (Ab184699)
ERK1, PRKM3, MAPK3, Mitogen-activated protein kinase 3, MAP kinase 3, MAPK 3, ERT2, Extracellular signal-regulated kinase 1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, Microtubule-associated protein 2 kinase, p44-ERK1, ERK-1, p44-MAPK, ERK2, PRKM1, PRKM2, MAPK1, Mitogen-activated protein kinase 1, MAP kinase 1, MAPK 1, ERT1, Extracellular signal-regulated kinase 2, MAP kinase isoform p42, Mitogen-activated protein kinase 2, ERK-2, p42-MAPK, MAP kinase 2, MAPK 2
详细信息
背景信息
What is this antibody validated in? Anti-ERK1 + ERK2 antibody [EPR17526] (ab184699) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Immunoprecipitation (IP), Immunocytochemistry/immunofluorescence (ICC/IF) in Human, Mouse, Rat samples. What is the molecular weight of ERK1 + ERK2? Anti-ERK1 + ERK2 [EPR17526] (ab184699) specifically detects a band for ERK1 + ERK2 (UniProt: P28482) at a molecular weight of 43, 41kDa. Trusted by the scientific community Anti-ERK1 + ERK2 [EPR17526] (ab184699) was first used in a scientific publication in 2015 and has been cited over 250 times in peer-reviewed journals. Specificity confirmed The specificity of Anti-ERK1 + ERK2 antibody [EPR17526] (ab184699) has been confirmed by Western blot testing in MAPK1 Knockout HeLa cell line, ab265052. Other related products We have a range of other formats of antibody clone [EPR17526] also available for your convenience: ab184699, Carrier free - ab242993 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl. Discover our selection of trial-size antibodies.
文献引用 (378)
LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1/LTBP1/TGF-β axis.
LTA4H 通过靶向 HNRNPA1/LTBP1/TGF-β 轴改善肿瘤微环境并阻止 HCC 进展
HVJ-E links Apolipoprotein d to antitumor effects
HVJ-E 将载脂蛋白 d 与抗肿瘤作用联系起来
Dysregulation of sphingolipid metabolism contributes to the pathogenesis of chronic myeloid leukemia.
鞘脂代谢失调是慢性粒细胞白血病发病机制中的一个因素
RAB26 promotes prostate cancer progression via the MAPK/ERK-TWIST1 signaling axis.
RAB26 通过 MAPK/ERK-TWIST1 信号通路促进前列腺癌进展
FOXC1-mediated serine metabolism reprogramming enhances colorectal cancer growth and 5-FU resistance under serine restriction
FOXC1 介导的丝氨酸代谢重编程增强丝氨酸限制下的结肠直肠癌生长和 5-FU 耐药性
Leveraging AAV1-Rac1T17N to prevent experimental proliferative vitreoretinopathy.
利用 AAV1-Rac1T17N 预防实验性增生性玻璃体视网膜病变
Single-cell multi-dimensional data analysis decodes RNF19A-mediated drug resistance in rheumatoid arthritis fibroblast-like synoviocytes: mechanisms and biological insights.
单细胞多维数据分析揭示了类风湿性关节炎成纤维细胞样滑膜细胞中 RNF19A 介导的耐药性:机制和生物学见解
Unique characteristics of autoantibodies targeting MET in patients with breast and lung cancer.
乳腺癌和肺癌患者中针对MET的自身抗体的独特特征
DUSP4 inhibited tumor cell proliferation by downregulating glycolysis via p-ERK/p-PGK1 signaling in ovarian cancer.
DUSP4 通过 p-ERK/p-PGK1 信号通路下调糖酵解,从而抑制卵巢癌肿瘤细胞增殖
BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer
BTG2缺陷型肥大细胞重塑肿瘤及肿瘤引流淋巴结微环境,导致乳腺癌化疗耐药。
- 1
- 2
- 3
- 4
- 5
- 6
- 38